Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Free Cash Flow: 2020-2024

Historic Free Cash Flow for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to -$14.5 million.

  • Immuneering's Free Cash Flow fell 21.54% to -$14.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$55.1 million, marking a year-over-year decrease of 11.71%. This contributed to the annual value of -$55.1 million for FY2024, which is 11.71% down from last year.
  • According to the latest figures from Q4 2024, Immuneering's Free Cash Flow is -$14.5 million, which was down 7.74% from -$13.5 million recorded in Q3 2024.
  • Immuneering's 5-year Free Cash Flow high stood at -$3.5 million for Q3 2020, and its period low was -$15.5 million during Q1 2024.
  • For the 3-year period, Immuneering's Free Cash Flow averaged around -$12.4 million, with its median value being -$12.0 million (2023).
  • Data for Immuneering's Free Cash Flow shows a maximum YoY slumped of 159.08% (in 2021) over the last 5 years.
  • Immuneering's Free Cash Flow (Quarterly) stood at -$5.5 million in 2020, then crashed by 68.49% to -$9.3 million in 2021, then dropped by 27.73% to -$11.8 million in 2022, then dropped by 1.08% to -$11.9 million in 2023, then decreased by 21.54% to -$14.5 million in 2024.
  • Its last three reported values are -$14.5 million in Q4 2024, -$13.5 million for Q3 2024, and -$11.6 million during Q2 2024.